Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland

Cancer ◽  
2002 ◽  
Vol 94 (8) ◽  
pp. 2211-2216 ◽  
Author(s):  
Afina S. Glas ◽  
Harry Hollema ◽  
Raoul E. Nap ◽  
John T. Plukker
Keyword(s):  
Estrogen Receptor ◽  
Growth Factor ◽  
Progesterone Receptor ◽  
Parotid Gland ◽  
Pleomorphic Adenoma ◽  
Growth Factor Receptor ◽  
Insulin Like Growth Factor ◽  
Mib 1 ◽  
Recurrent Pleomorphic Adenoma

scholarly journals Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma

2019 ◽  
Vol 12 ◽  
pp. 2632010X1987338
Author(s):  
Ana Amélia de Souza ◽  
Albina Altemani ◽  
Ney Soares de Araujo ◽  
Lucas Novaes Texeira ◽  
Vera Cavalcanti de Araújo ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Salivary Gland ◽  
Progesterone Receptor ◽  
Pleomorphic Adenoma ◽  
Malignant Transformation ◽  
Growth Factor Receptor ◽  
Salivary Gland Neoplasm ◽  
Carcinoma Ex Pleomorphic Adenoma ◽  
Her 2 ◽  
Recurrent Pleomorphic Adenoma

Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted cancer therapy in various tumors, including salivary gland tumors. The aim of this study was to investigate the role of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) in PA, RPA, and CXPA. In total, 20 cases of PA, 18 of RPA, and 7 cases of CXPA were immunohistochemically studied for ER, PR, and HER-2. For evaluation of ER and PR, only nuclear expression and greater than 10% positive cells were regarded as cutoff criteria. HER-2 was evaluated semiquantitatively and graded from 0 to 3+. HER-2 amplification was assessed by chromogenic in situ hybridization (CISH). Tumors were negative for ER, PR, and HER-2 in all cases of PA and RPA. A case of CXPA showed moderate and complete membranous staining, and 6 cases were negative. HER-2 amplification was not observed in any case. In conclusion, the lack of ER, PR, and HER-2 expression in PA, RPA, and CXPA suggests that these proteins are not involved in progression, recurrence, or malignant transformation of PA.

Sign in / Sign up

Export Citation Format

Share Document